Q-omics provides the consensus-scored TBX4 profile across patient tissues and cancer cell-line models. TBX4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TBX4 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, TBX4 RNA expression shows 13,461 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUAD, and TGCT as cancer lineages where TBX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX4 survival associations across molecular data types. TBX4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX4 RNA expression–survival associations across cancer types. High TBX4 expression shows unfavorable associations in ACC, UVM, LIHC, LGG and KIRP, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TBX4 RNA expression.
This table summarizes TBX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TBX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX4 shows lower tumor expression in LUAD, LUSC and BLCA and higher tumor expression in KIRC, HNSC and LIHC. The LUAD box plot shows higher TBX4 RNA expression in normal versus tumor tissue (log2 FC = −2.642, t-test p < 0.001).
This table shows molecular features associated with TBX4 in patient tissues and cancer cell lines. In patient samples, TBX4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
